SELECTION OF DOSE REGIMENS OF AZITHROMYCIN

被引:83
作者
FOULDS, G [1 ]
JOHNSON, RB [1 ]
机构
[1] PFIZER INC, DEPT CLIN RES, DIV CENT RES, GROTON, CT 06340 USA
关键词
D O I
10.1093/jac/31.suppl_E.39
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The unique pharmacokinetics of azithromycin are characterized by high, sustained tissue concentrations. The concentrations of azithromycin were predicted, following various multiple dose regimens, from concentrations in tonsillar, prostatic, and uterine tissues following single oral doses. Following a five-day treatment regimen (500 mg on day 1, followed by 250 mg on days 2–5), or a three-day regimen (500 mg daily for three days), concentrations of azithromycin in tonsillar tissue, representative of respiratory tract tissues, will continuously be greater than the MICs for key target pathogens (Streptococcus pyogenes, Haemophitus influenzae, Staphylococcus aureus) in infections of the respiratory tract for up to 10 days. Since tissue concentrations above the MICs for infecting organisms were correlated with efficacy in animal models of infection, short treatment regimens consisting of once-daily oral administration of azithromycin should be effective in the treatment of a variety of infections. A single 1 g oral dose will provide concentrations in the uterus and prostate, representing urogcnital tissues, above the MIC for Chlamydia trachomatis for approximately 10 days. Thus, this regimen should be effective in the treatment of chlamydial infections of the genital tract. © 1993, The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:39 / 50
页数:12
相关论文
共 57 条
  • [1] INVITRO ACTIVITY OF ERYTHROMYCIN, ROXITHROMYCIN AND CP-62993 AGAINST COMMON PEDIATRIC PATHOGENS
    ARONOFF, SC
    LAURENT, C
    JACOBS, MR
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (02) : 275 - 276
  • [2] BALDWIN DR, 1990, EUR RESPIR J, V3, P886
  • [3] COMPARATIVE-STUDY OF AZITHROMYCIN AND AMOXICILLIN CLAVULANIC ACID IN THE TREATMENT OF LOWER RESPIRATORY-TRACT INFECTIONS
    BALMES, P
    CLERC, G
    DUPONT, B
    LABRAM, C
    PARIENTE, R
    POIRIER, R
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1991, 10 (05) : 437 - 439
  • [4] INVITRO ACTIVITIES OF AZITHROMYCIN (CP-62,993), CLARITHROMYCIN (A-56268-TE-031), ERYTHROMYCIN, ROXITHROMYCIN, AND CLINDAMYCIN
    BARRY, AL
    JONES, RN
    THORNSBERRY, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (05) : 752 - 754
  • [5] BERGAN T, 1984, SCAND J INFECT DIS, P83
  • [6] BERGAN T, 1992, SCAND J INFECT DIS, P15
  • [7] INVITRO AND INVIVO INTRALEUKOCYTIC ACCUMULATION OF AZITHROMYCIN (CP-62, 993) AND ITS INFLUENCE ON EXVIVO LEUKOCYTE CHEMILUMINESCENCE
    BONNET, M
    VANDERAUWERA, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (06) : 1302 - 1309
  • [8] SYNTHESIS, INVITRO AND INVIVO ACTIVITY OF NOVEL 9-DEOXO-9A-AZA-9A-HOMOERYTHROMYCIN A DERIVATIVES - A NEW CLASS OF MACROLIDE ANTIBIOTICS, THE AZALIDES
    BRIGHT, GM
    NAGEL, AA
    BORDNER, J
    DESAI, KA
    DIBRINO, JN
    NOWAKOWSKA, J
    VINCENT, L
    WATROUS, RM
    SCIAVOLINO, FC
    ENGLISH, AR
    RETSEMA, JA
    ANDERSON, MR
    BRENNAN, LA
    BOROVOY, RJ
    CIMOCHOWSKI, CR
    FAIELLA, JA
    GIRARD, AE
    GIRARD, D
    HERBERT, C
    MANOUSOS, M
    MASON, R
    [J]. JOURNAL OF ANTIBIOTICS, 1988, 41 (08) : 1029 - 1047
  • [9] Carlier M.B., 1991, 31 INT C ANT AG CHEM, P184
  • [10] CARS O, 1991, SCAND J INFECT DIS, P23